Items where authors include "Greatorex, N."

Article

Munir, T., Girvan, S., Cairns, D.A. orcid.org/0000-0002-2338-0179 et al. (32 more authors) (2025) Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia. The New England Journal of Medicine. ISSN 0028-4793

Munir, T., Cairns, D.A. orcid.org/0000-0002-2338-0179, Bloor, A. et al. (29 more authors) (2023) Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease. New England Journal of Medicine. ISSN 0028-4793

Hillmen, P., Pitchford, A., Bloor, A. et al. (29 more authors) (2023) Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, 24 (5). pp. 535-552. ISSN 1470-2045

Proceedings Paper

Danson, S., Collinson, M., Plummer, E.R. et al. (17 more authors) (2025) Comparison of 1 year versus minimum 2 years of anti-PD1-based immunotherapy as first-line treatment for metastatic melanoma: Results of the DANTE phase III trial. In: Journal of Clinical Oncology. 2025 ASCO Annual Meeting II, 30 May - 03 Jun 2025, Chicago, USA. American Society of Clinical Oncology (ASCO) .

Rawstron, A., Webster, N., Dalal, S. et al. (15 more authors) (2023) Using Peripheral Blood (PB) Measurable Residual Disease (MRD) Levels to Predict <0.01% Bone Marrow Disease (BM uMRD4): Identification of Effective PB Targets for CLL Treatment Cessation in the Ibrutinib+Venetoclax Arm of the FLAIR Trial. In: Blood. 65th ASH: Annual Meeting & Exposition, 09-12 Dec 2023, San Diego, USA. American Society of Hematology , p. 632.